Why Alzamend Neuro Stock Soared Today
Shares of Alzamend Neuro (NASDAQ: ALZN) surged 28% on Tuesday, as investors bought in ahead of the biotech's upcoming clinical data release for its experimental Alzheimer's treatment.
Alzamend is an early stage biopharmaceutical company focused on creating therapies for neurodegenerative diseases and psychiatric conditions. Its investigational oral treatment for dementia related to Alzheimer's, AL001, has been shown to prevent cognitive impairment in mice.
Alzamend is currently conducting a phase 1 human clinical study to evaluate the safety and proper dosing for AL001 in a planned phase 2 trial. The biotech said in late November that it expected to deliver top-line data for its phase 1 study in "mid- to late-December."
Source Fool.com
